Santarus, Inc. (NASDAQ:SNTS.DL)

CAPS Rating: No stars

A pharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by gastroenterologists or primary care physicians.


Player Avatar mchedester (77.05) Submitted: 3/26/2013 5:22:32 AM : Outperform Start Price: $17.66 SNTS.DL Score: +62.27

Forward eps hasn't caught up to growth rate. The only reason this isn't much higher is because it has already gone up so much in the past months. Luckily the market doesn't let anything go straight up and this is where some profit can be made.

Featured Broker Partners